New Ultra-Low-Dose Combination Pill Shows Superior Blood Pressure Control in South Korean Study

A groundbreaking clinical trial has demonstrated the efficacy of a novel ultra-low-dose combination pill for hypertension, developed by South Korean researchers. This single pill integrates three distinct blood pressure medications, amlodipine, losartan, and chlorthalidone, at one-third of their standard dosages.

The study, involving over 20 hospitals and patients with mild to moderate hypertension, found that the ultra-low-dose triple combination pill significantly outperformed the standard dose of losartan alone in controlling systolic blood pressure. It also showed comparable effectiveness to amlodipine monotherapy, while offering a reduced burden of medication for patients.

Hypertension affects one in three South Korean adults, but low treatment adherence due to the inconvenience of taking multiple pills poses a significant challenge. This new combination pill aims to address this issue by improving patient compliance and potentially revolutionizing hypertension treatment. The research team highlighted that the combination strategy, using drugs with different mechanisms of action, effectively lowers blood pressure while minimizing side effects.

Safety assessments confirmed a low incidence of serious adverse events, with less than 1% of patients experiencing severe side effects. Notably, common side effects like leg swelling, often associated with calcium channel blockers, were not reported. The findings, published in the Journal of the American College of Cardiology, suggest a promising new direction for managing hypertension, though long-term efficacy and safety require further observation.

"This is the first Phase 3 clinical trial to demonstrate that an ultra-low-dose combination of three ingredients is superior to existing standard single-drug treatments in terms of efficacy and safety," said Professor Sung Ki-cheol of Kangbuk Samsung Hospital. "We expect it to improve medication convenience and enhance the stagnant blood pressure control rate."

“

This is the first Phase 3 clinical trial to demonstrate that an ultra-low-dose combination of three ingredients is superior to existing standard single-drug treatments in terms of efficacy and safety. We expect it to improve medication convenience and enhance the stagnant blood pressure control rate.